Talaris Therapeutics, Inc. is a late-clinical stage biotechnology company that is developing a single-dose cell therapy that seeks to free organ transplant recipients of the burdens and toxicities of lifelong immunosuppression.
Location: United States, Kentucky, Louisville
Employees: 51-200
Phone: +1 502-398-9250
Total raised: $365M
Founded date: 1988
Investors 3
| Date | Name | Website |
| 19.11.2020 | Logos Capi... | logoscapit... |
| 31.10.2020 | Aisling Ca... | aislingcap... |
| - | Longitude ... | longitudec... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 07.05.2021 | - | $150M | - |
| 06.10.2020 | Series B | $115M | - |
| 18.04.2019 | Series A | $100M | - |
Mentions in press and media 10
| Date | Title | Description |
| 07.05.2021 | Talaris Therapeutics’ IPO raises $150M to transform solid organ transplants | Organ transplants may offer patients a new shot at life, but the procedure is just the beginning of a new set of potential medical problems. Patients require chronic drug therapy to prevent the immune system from rejecting the organ. Those ... |
| 06.10.2020 | Talaris Therapeutics Closes $115 Million Series B Financing | Proceeds to support ongoing Phase 3 registration trial of Talaris’ lead product candidate FCR001 in living donor kidney transplant, and additional Phase 2 trials next year in autoimmune disease and organ transplant Financing co-led by Surv... |
| 06.10.2020 | Talaris Therapeutics bags another $115M to curb immunosuppression in organ transplant patients | Just over a year after securing a $100 million Series A round, Talaris Therapeutics is back with a $115 million Series B to fuel its mission of making organ transplants safer. CEO Scott Requadt said he’s seen “dramatic pr... |
| 06.10.2020 | Talaris Therapeutics Closes $115 Million Series B Financing | BOSTON & LOUISVILLE, Ky.--(BUSINESS WIRE)--Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indicati... |
| 06.10.2020 | Talaris Therapeutics Inks $115M Series B | BOSTON, MA, Talaris Therapeutics has announced the closing of a $115 million Series B financing. >> Click here for more funding data on Talaris Therapeutics >> To export Talaris Therapeutics funding data to PDF and Excel, cl... |
| 19.04.2019 | Term Sheet — Friday, April 19 | SOARING “I have no idea why.” Paid Content Securing the enterprise without boundaries From ExtraHop Asked whether Zoom had left money on the table by pricing its shares too low, Yuan said that Wall Street’s reaction was “out of our control.... |
| 18.04.2019 | Talaris Therapeutics Raises $100M Series A Financing | BOSTON & LOUISVILLE, Ky.--(BUSINESS WIRE)--Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for orga... |
| 18.04.2019 | Talaris Therapeutics Raises $100M in Series A Financing | Talaris Therapeutics, Inc., a Boston, MA and Louisville, KY-based biotechnology company developing cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, closed a $100m S... |
| 18.04.2019 | Talaris Therapeutics Nabs $100M | BOSTON, MA, Talaris Therapeutics today announced the closing of a $100 million Series A financing. >> Click here for more funding data on Talaris Therapeutics >> To export Talaris Therapeutics funding data to PDF and Excel, ... |
| - | Talaris Therapeutics’ IPO raises $150M to transform solid organ transplants | Organ transplants may offer patients a new shot at life, but the procedure is just the beginning of a new set of potential medical problems. Patients require chronic drug therapy to prevent the immune system from rejecting the organ. Those ... |